To further put these changes into clinical context, we previously measured IOS in response to propranolol-induced bronchoconstriction in patients with asthma where there was a 0.05 (kPa/L) $ s increase in R5 2 R20 corresponding to a 104.1% (95% CI, 22.6 to 185.6%) change, along with a subsequent bronchodilator response to salbutamol of 20.17 (kPa/L) $ s and 2115.6% (95% CI, 255.6% to 2175.7%), respectively (2). Moreover, in a health informatics evaluation of 302 patients with asthma, there was a 45% increased risk for worse control in relation to oral corticosteroid use, and 47% in relation to inhaled albuterol use measured during a 2-year period when comparing cohorts of patients with asthma, using a cutoff value for R5 2 R20 of less than or greater than 0.07 (kPa/L) $ s (3).
Reply to Lipworth and Kuo
From the Author: I thank Prof. Lipworth and Dr. Kuo for their comments on our manuscript (1) . Our attempt is the first of its kind to link patient-based computational models of the small airways with patient outcome measures. In line with the comments made by Prof. Lipworth with respect to resistance at 5 Hz (R5) 2 resistance at 20 Hz (R20) and asthma risk in cross-sectional studies, I and others recently reported the results of the ATLANTIS (Assessment of Small Airways Involvement in Asthma) study, a large multinational study evaluating the association of small airway disease with adult asthma outcomes (2) .
ATLANTIS clearly identified that the oscillometry measure R5 2 R20 was one of the strongest predictors of both asthma control and prior asthma exacerbations among all the potential small airway indices.
The combination of our findings (1) with the ATLANTIS study results (2) should now enable investigators to test interventions that target the small airways, with R5 2 R20 as an outcome measure. n
